Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97

Eva HavrdovaCharles University in Prague, First Faculty of Medicine, Department of Neurology, Prague, Czech Republic+420224966422; +420224917907; [email protected]

, MD PhD,

Michael HutchinsonSt Vincent's University Hospital, Dublin, Ireland

, MD,

Nuwan C KurukulasuriyaMedical Affairs, Biogen Idec Inc., Weston, MA, USA

, PhD,

Kartik RaghupathiBiogen Idec Inc., Weston, MA, USA

, MS,

Marianne T SweetserSafety and Benefit-Risk Management, Biogen Idec Inc., Weston, MA, USA

, MD PhD,

Katherine T DawsonMS Clinical Development, Biogen Idec Inc., Weston, MA, USA

, MD &

Ralf GoldSt. Josef-Hospital/Ruhr-University Bochum, Neurological Clinic, Department of Neurology, Bochum, Germany

, MD show all

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date